MEDI 6389
Alternative Names: MEDI-6389Latest Information Update: 28 Nov 2023
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Staphylococcal-infections in France
- 02 Oct 2019 Preclinical trials in Staphylococcal infections in France (Parenteral) before October 2019
- 02 Oct 2019 Pharmacodynamics data from preclinical studies for prosthetic joint infection presented at the IDWeek 2019(IDW-2019)